Shots:

• The P-III IMbrave150 study involve assessing of Tecentriq (1200mg- IV) + Avastin (IV- 15 mg/kg) vs Sorafenib (PO- 400mg- bid) in 501 patients in a ratio 2:1 with unresectable HCC prior not treated with systemic therapies
• The P-III IMbrave 150 study results: 42% reduction in risk of death- 41% reduction in risk of disease worsening; mOS (not reached vs 13.2mos.); mPFS (6.8 mos. vs 4.3mos.) measured as per IRF RECIST v1.1.; median follow-up 8.6 months; AEs (57% vs 55%)- presented at ESMO Congress 2019
• Tecentriq is mAb targeting PD-L1 which is expressed on tumor cells and tumor-infiltrating immune cells- blocking its interactions with both PD-1 and B7.1receptors. The dual regimen combat multiple cancer indications as Avastin enhances Tecentriq ability to restore anti-cancer immunity- by inhibiting VEGF related immunosuppression

Click here to­ read full press release/ article 

Ref: Roche | Image: Roche